LXRX News and Press, Lexicon Pharmaceuticals Inc. From 11/08/23

2023-11-08 07:08:47 ET More on Lexicon Pharmaceuticals Looking Back In On Lexicon Pharmaceuticals Lexicon Pharmaceuticals Underway With Inpefa, But A Lot Of Hard Work Lexicon Rolls Out Inpefa For Heart Failure Amid Robust Competition Lexicon to present data o...

Commercial launch of INPEFA ® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community Significant formulary inclusions effective in Q4 opening...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Lexicon Pharmaceuticals Inc. (LXRX) is expected to report $-0.22 for Q3 2023

2023-11-07 11:49:17 ET Lexicon Pharmaceuticals ( NASDAQ: LXRX ) is scheduled to announce Q3 earnings results on Wednesday, November 8th, before market open. The consensus EPS Estimate is -$0.22 and the consensus Revenue Estimate is $2.06MOver the last 3 months, EPS estimat...

2023-11-07 10:58:25 ET Major earnings expected before the bell on Wednesday include: Biogen ( BIIB ) 3D Systems ( DDD ) Roblox ( RBLX ) Teva Pharmaceutical Industries ( TEVA ) Warner Bros. Discovery ( WBD ) For further details see: Notable...

THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8 th , 2023 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m...

Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure...

As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 01, 2023 (G...

Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cu...